Document Type : Research articles
Authors
1 Zunyi Medical University, Zunyi 563000, China & Department of Hematology, Southwest Hospital, First Affiliated Hospital of the Army Medical University, Chongqing 400038, China
2 Department of Hematology, Southwest Hospital, First Affiliated Hospital of the Army Medical University, Chongqing 400038, China
3 Medical College of Guizhou University, Guiyang 550025, China
Abstract
Hepatic sinusoidal occlusion syndrome (SOS) or venous occlusive disease (VOD) is a frequent complication of allogeneic Hematopoietic stem cell transplantation (allo-HSCT). The mortality rate of patients with severe VOD is extremely high. It is of utmost importance to explore practical ways to reduce the incidence of VOD. The present study aimed to evaluate the efficacy and safety of a prophylaxis strategy involving the combined use of prostaglandin E1 (PGE1), dalteparin, low molecular weight glucan dextran (LMWD), and ursodeoxycholic acid (UDCA). We conducted a single-center retrospective clinical observation of 225 patients who received allo-HSCT for hematological disorders between 2008 and 2022, all of whom received these four medicines for VOD. These 225 patients were within the age range of 6-58 years, and their donors were classified as related donors (75.5%) and unrelated donors (24.5%). All patients underwent a myeloablative conditioning regimen prior to transplantation. Each patient possessed at least one risk factor for VOD, and 167 (74.2%) cases were deemed to be at high risk. Ultimately, only two patients developed VOD, with an incidence of only 0.89%, of whom one was late-onset VOD. The bleeding rate was 32.9%, with predominantly grade 1-2 (93.2%). The incidence of bleeding aligns with findings reported in other literature. Remarkably, the mortality rate associated with bleeding during transplantation was a mere 1.8%, significantly lower than the average. The results of the study demonstrated the effectiveness and safety of the four PGE1-based medications in the prevention of VOD after allo-HSCT.
Keywords
- de Ledinghen V, Villate A, Robin M, Decraecker M, Valla D, Hillaire S, et al. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol. 2020;44(4):480-5. doi: 10.1016/j.clinre. 2020.03.019. [PubMed: 32253162].
- Özkan HA, Özkan SG. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation in adult patients: Diagnosis, incidence, prophylaxis, and treatment. Transfus Apher Sci. 2022;61(1):103372. doi: 10.1016/j.transci.2022.103372. [PubMed: 35101376].
- Xia Y, Qin H, Yang J. Hepatic veno-occlusive disease development in the hematopoietic stem cell transplantation patients: incidence and associated risk factors, a meta-analysis. Eur J Gastroenterol Hepatol. 2021;33(6):872-84. doi: 10.1097/MEG. 0000000000001802. [PubMed: 32639417].
- Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906-12. doi: 10.1038/bmt.2016.130. [PubMed: 27183098].
- Yoon JH, Min GJ, Park SS, Park S, Lee SE, Cho BS, et al. Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1. Bone Marrow Transplant. 2021;56(7):1603-13. doi: 10.1038/s41409-021-01215-y. [PubMed: 33526915].
- Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157-68. doi: 10.1016/j.bbmt.2009.08.024. [PubMed: 19766729].
- Hong CR, Choi Y, Oh J, Sunwoo J, Hong KT, Choi JY, et al. Pharmacokinetic analysis of continuous intravenous infusion of lipo-prostaglandin E1 As a prophylaxis of hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Blood. 2016;128(22):2214. doi: 10.1182/ blood.V128.22.2214.2214.
- Gluckman E, Jolivet I, Scrobohaci ML, Devergie A, Traineau R, Bourdeau‐Esperou H, et al. Use of prostaglandin E1 for prevention of liver veno‐occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol. 1990;74(3):277-81. doi: 10.1111/j.1365-2141.1990.tb02583.x. [PubMed: 2159315].
- Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(2):206-17. Doi: 10.1016/j.bbmt.2006.09.012. [PubMed: 17241926].
- Imran H, Tleyjeh IM, Zirakzadeh A, Rodriguez V, Khan SP. Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. Bone Marrow Transplant. 2006;37(7):677-86. doi: 10.1038/sj.bmt.1705297. [PubMed: 16489362].
- Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood. 1992;79(11):2834–40. [PubMed: 1586733].
- Or R, Nagler A, Shpilberg O, Elad S, Naparstek E, Kapelushnik J, et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation. 1996;61:1067–71. doi: 10.1097/ 00007890-199604150-00014. [PubMed: 8623187].
- Stutz L, Halter JP, Heim D, Passweg JR, Medinger M. Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin. Bone Marrow Transplant. 2022;57(3):391-8. doi: 10.1038/s41409-021-01546-w. [PubMed: 34980902].
- Hao J, Deng L, Li Y. Effect of heparin combined with prostaglandin and compound Danshen on prevention of hepatic vein obstruction after hematopoietic stem cell transplantation. Chongqing Med. 2014;13:1540-2.
- Robitaille N, Lacroix J, Alexandrov L, Clayton L, Cortier M, Schultz KR, et al. Excess of veno-occlusive disease in a randomized clinical trial on a higher trigger for red blood cell transfusion after bone marrow transplantation: a Canadian blood and marrow transplant group trial. Biol Blood Marrow Transplant. 2013;19(3):468-73. doi: 10.1016/j.bbmt.2012. 12.002. [PubMed: 23220014].
- CHS, CMA. The consensus of allogeneic hematopoietic transplantation for hematological diseases in China (2014)--indication, conditioning regimen and donor selection. Zhonghua Xue Ye Xue Za Zhi. 2014;35(8):775-80. doi: 10.3760/cma.j.issn.0253-2727.2014.08.029. [PubMed: 25 152138].
- SCAG, CSH, CMA. Chinese consensus of allogeneic hematopoietic stem cell transplantation for hematological disease (Ⅲ) -acute graft-versus-host disease (2020). Zhonghua Xue Ye Xue Za Zhi. 2020;9(7):529-36. doi: 10.3760/cma.j.issn.0253-2727.2020.07. 001. [PubMed: 32549120].
- Bonifazi F, Barbato F, Ravaioli F, Sessa M, Defrancesco I, Arpinati M, et al. Diagnosis and treatment of VOD/SOS after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020;11:489. doi: 10.3389/fimmu.2020.00489. [PubMed: 32318059].
- Mohty M, Malard F, Abecasis M, Aerts E, Alaskar AS, Aljurf M, et al. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplant. 2020;55(3):485-95. doi: 10.1038/s41409-019-0705-z. [PubMed: 31576023].
- Sola M, Bhatt V, Palazzo M, Cavalier KE, Devlin SM, Maloy M, et al. Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant. Bone Marrow Transplant. 2022;57(7):1095-100. doi: 10.1038/s41409-022-01689-4. [PubMed: 35477992].
- Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379(9823):1301-9. doi: 10.1016/S0140-6736(11)61938-7. [PubMed: 22364685].
- Tsirigotis PD, Resnick IB, Avni B, Grisariu S, Stepensky P, Or R, et al. Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen. Bone Marrow Transplant. 2014;49(11):1389-92. doi: 10.1038/bmt.2014.168. [PubMed: 25068424].
- Qin CJ, Liu LJ, Zhang ZM, Luo L, Lai YR, Li QC. A clinical analysis of hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Zhonghua Nei Ke Za Zhi. 2018;57(7):483-6. doi: 10.3760/cma.j.issn.0578-1426.2018.07.003. [PubMed: 29996265].
- Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno‐occlusive disease after stem cell transplantation. Am J Hematol. 2000;64(1):32-8. doi: 10.1002/(sici)1096-8652(200005)64: 1<32::aid-ajh6>3.0.co;2-n. [PubMed: 10815785].
- Lee SH, Yoo KH, Sung KW, Koo HH, Kwon YJ, Kwon MM, et al. Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Bone Marrow Transplant. 2010;45(8):1287-93. doi: 10.1038/ bmt.2009.349. [PubMed: 20010866].
- Song JS, Seo JJ, Moon HN, Ghim T, Im HJ. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children. J Korean Med Sci. 2006;21(5):897-903. doi: 10.3346/jkms.2006.21.5.897. [PubMed: 17043426].
- Kumar S, Deleve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation for thalassemia major: incidence, management, and outcome. Bone Marrow Transplant. 2021;56(7):1635-41. doi: 10.1016/j.bbmt. 2015.09.024.
- Ruutu T, Juvonen E, Remberger M, Remes K, Volin L, Mattsson J, et al. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant. 2014; 20(1):135-8. doi: 10.1016/j.bbmt.2013.10.014. [PubMed: 24141008].
- Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016;22(3):400-9. doi: 10.1016/j.bbmt.2015.09. 024. [PubMed: 26431626].
- Forrest DL, Thompson K, Dorcas VG, Couban SH, Pierce R. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Bone Marrow Transplant. 2003;31(12):1143-9. doi: 10.1038/sj.bmt. 1704087. [PubMed: 12796794].
- FU L, Zhang W, Wang J. Prophylaxis of hepatic veno-occlusive disease after HSC transplantation with lipo-prostaglandin E1 plus dextran 40. Med J Chin People's Lib Army. 2008;33(7):889-91.
- Labrador J, Lopez-Anglada L, Perez-Lopez E, Lozano FS, Lopez-Corral L, Sanchez-Guijo FM, et al. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. Haematologica. 2013;98(3):437-43. doi: 10.3324/haematol.2012.069559. [PubMed: 22899581].
- Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656-65. doi: 10.1182/blood-2015-10-676924. [PubMed: 26825712].
', './data/ircmj/coversheet/cover_en.jpg'))